Bryan Lebean, MD
Internal Medicine · Lafayette, LANPI 1821052754
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,449 of the $53,325 with a category attached, or 68.4%. 54 manufacturers reported payments, led by Bayer at 42.4% of the total. Reporting peaked in 2022 at $20,003 and has fallen 85.7% since, to $2,858 in 2025. Among internal medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 946 payments — averaging $56.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$23K
- Apria Healthcare LLC$8K
- Idorsia Pharmaceuticals US Inc$7K
- Novo Nordisk$2K
- AstraZeneca$2K
- Harmony Biosciences LLC$1K
- plus $10K from 48 others
What the payments were for
- Consulting fees$1490%
- Speaking & faculty fees$36,44968%
- Travel & lodging$1130%
- Food & beverage$16,41531%
- Education$1990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,325 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 379 | $477,221 |
| XywavSodium,calcium,mag,pot Oxybate | 13 | $207,005 |
| JardianceEmpagliflozin | 175 | $178,758 |
| FarxigaDapagliflozin Propanediol | 158 | $157,558 |
| LinzessLinaclotide | 174 | $143,900 |
| TrulicityDulaglutide | 84 | $142,682 |
| JanuviaSitagliptin Phosphate | 138 | $131,031 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $88,887 |
| EliquisApixaban | 62 | $56,537 |
| TradjentaLinagliptin | 55 | $55,505 |
| EntrestoSacubitril/Valsartan | 48 | $48,064 |
| MounjaroTirzepatide | 42 | $46,480 |
| TrintellixVortioxetine Hydrobromide | 60 | $35,532 |
| KerendiaFinerenone | 37 | $34,731 |
| VascepaIcosapent Ethyl | 58 | $30,310 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $2,472 | $495,716393 claims |
| Boehringer IngelheimJardiance, Tradjenta | $546 | $234,263230 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,023 | $189,161126 claims |
| AstraZenecaFarxiga, Symbicort | $1,541 | $161,834173 claims |
| AbbVieLinzess, Namzaric | $303 | $155,864186 claims |
| MerckJanuvia, Belsomra | $236 | $138,710155 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $878 | $112,942122 claims |
| PfizerEliquis | $280 | $56,53762 claims |
| NovartisEntresto | $452 | $48,06448 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $563 | $43,25980 claims |
| BayerKerendia | $22,590 | $34,73137 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $89 | $26,89476 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Lafayette
- Nethuja SalagundlaLafayette$32K
- Hector RoblesLafayette$19K
- Brad BroussardLafayette$17K
- Juan Perez-RuizLafayette$12K
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
- Bruce SamuelsCovington$200K
- Amanda FontenotMarrero$142K
- John SchwabBaton Rouge$122K
- Daniel EnglertNew Orleans$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.